A self-activating orphan receptor by Krumm, B. & Roth, B.L.
G­protein­coupled receptors are the largest 
class of membrane protein in the human
genome, and represent the most abundant 
pharmaceutical targets. More than 800 such 
receptors are known in humans, of which per­
haps 100 are orphan receptors — those for 
which the naturally occurring (endo genous) 
ligand molecules that bind to and activate 
them have yet to be identified1,2. This lack of 
understanding of orphan G­protein­coupled 
receptors (oGPCRs) impedes our ability to 
exploit their potential as therapeutic targets. 
On page 152, Lin et al.3 close this gap in knowl­
edge by reporting the first 3D structure of a 
full­length oGPCR, GPR52, in multiple states.
GPR52 is a potential drug target for treating 
several neuropsychiatric disorders, including 
Huntington’s disease and schizophrenia. When 
activated, it selectively binds to the Gs family 
of G proteins inside cells, and thereby stim­
ulates the production of cyclic AMP (cAMP) 
signalling molecules, which regulate various 
cellular processes. Efforts to find drugs that 
target GPR52 would benefit from a greater 
knowledge of how the receptor couples to Gs 
and its activation process.
Lin et al. began their investigation of the 
structural basis for GPR52 activation using 
X­ray crystallography. In their initial stud­
ies, the authors used a variety of strategies, 
including extensive protein engineering, to 
both stabilize the receptor and enable its 
production in sufficient quantities to pro­
duce high­resolution crystal structures. The 
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Figure 1 | Binding sites in the receptor GPR52. Lin 
et al.3 report structures of the membrane receptor 
GPR52, a potential drug target for which the 
putative naturally occurring agonist — the ligand 
molecule that activates the receptor — is unknown. 
The authors find that a region of GPR52 known as 
extracellular loop 2 (ECL2) binds to a site in the 
receptor that is analogous to the agonist­binding 
site in other receptors from the same family. ECL2 
seems to activate the receptor, removing the need 
for an external agonist. The authors also find that 
the synthetic molecule c17, which activates GPR52, 
binds to a different region next to the site bound 
by ECL2, and might therefore be an allosteric 
modulator (a compound that potentiates the 
activity of the receptor but does not bind at the 
agonist­binding site).
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structures. Moreover, if the approaches used 
by Lin et al. for the structural elucidation 
of GPR52 are applied to other oGPCRs that 
have high constitutive activity5,6, they might 
transform our understanding of oGPCRs and 
accelerate their therapeutic exploitation.
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an external agonist is truly striking. The new 
findings raise the intriguing possibility that, 
for at least some oGPCRs, the incorporation of 
agonists within the receptor itself obviates the 
need for external ligands. Indeed, several other 
oGPCRs that have high constitutive activities5 
have been identified, along with others that 
don’t have sodium­binding sites6. 
It should be kept in mind that — as with all 
structural studies — Lin and colleagues’ work 
has provided only a few snapshots of the 
receptor structure. Further biochemical and 
biophysical studies will be essential to work 
out the details of GPR52’s dynamic behaviour 
under physiological conditions.
Nevertheless, the authors’ high­
resolution structures should aid the 
development of drugs that selectively 
target GPR52, but avoid other potential 
drug targets — for instance, by enabling 
computational studies7 in which ultra­large 
libraries of potential ligands are docked 
into the binding site revealed by the 
researchers thus obtained the structures of 
human GPR52 in the ligand­free (apo) state 
and in complex with c17, a synthetic molecule 
that acts as an agonist (that is, it activates the 
receptor).
Not unexpectedly, GPR52­apo adopts 
the GPCR architecture that has been seen 
in many other structures, involving seven 
transmembrane domains. Surprisingly, a 
region of the receptor known as extracellular 
loop 2 (ECL2) folds into what would normally 
be the binding site for an endogenous ligand 
(the orthosteric binding site), where it acts 
as a lid that blocks the entrance to this site 
(Fig. 1). Lin et al. observed that the activity of 
GPR52 is significantly diminished when ECL2 
is mutated or deleted, indicating that the 
loop is essential for signalling activity in the 
receptor’s native environment. Meanwhile, 
the crystal structure of the receptor in com­
plex with c17 suggests that this agonist binds 
to a ‘side pocket’ that has not been observed 
in previously reported structures of GPCRs. 
The authors therefore speculate that c17 acts 
allosterically — at a site remote from the ortho­
steric binding site — to potentiate GPR52’s 
activity.
Remarkably, the authors were then able to 
form a stable complex of GPR52 with a modi­
fied Gs protein in the absence of an agonist, and 
to obtain the structure of the complex using 
cryo­electron microscopy. The receptor in 
this complex has the structural hallmarks of 
previously visualized, active GPCRs captured 
in complex with G proteins1. The arrangement 
of ECL2 in this active­state structure is the 
same as in the crystal structure of GPR52­
apo, implying that ECL2 acts as a ‘tethered 
agonist’ under physiological conditions to 
facilitate signalling pathways in the absence 
of an endogenous agonist — similarly to the 
behaviour of some other GPCRs, such as 
the PAR1 protease­activated receptor4.
Most GPCRs have some basal (constitutive) 
activity wherein they spontaneously couple 
to their particular G proteins. The consti­
tutive activity of GPR52 is exceptionally 
high5. Indeed, Lin and colleagues find that 
GPR52’s basal activity is so great that the 
receptor’s ability to signal by increasing 
cAMP levels is only slightly augmented by 
the addition of c17. 
The authors report that this high level 
of constitutive activity is achieved by at least 
two structural features that are unusual for 
GPCRs: the lack of a binding site for sodium 
ions, and the occupation of an apparent 
agonist­binding site by the tethered agonist 
in ECL2. The sodi­um­binding site of GPCRs is 
known to be impor­tant for damping 
constitutive activity6, and so the observation 
that a GPCR that lacks such a site has a high 
level of basal activity is not entirely 
surprising. By contrast, the discovery of a 
tethered agonist that helps to maintain 
GPR52 in the active state in the absence 
of 
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